This volume, which includes contributions from leading scientists and
clinicians in the field, provides definitive, state-of-the-art
information on STAT inhibitors in a biological and clinical context. It
gives an overview of the biology of the STAT family of transcription
factors and their role in cancer etiology. Additionally, it describes
the raft of therapeutic approaches being used to inhibit STATs in the
context of various cancers, covering the full spectrum of therapeutic
approaches to inhibiting STATs, and presenting emerging data from
clinical trials.